Company Overview

At LAVA, we are focused on developing

our Gammabody™ platform

to transform cancer therapy. Our Gammabody™ platform generates bispecific gamma delta T cell engagers that specifically activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. This approach is designed to complement natural tumor recognition, direct Vγ9Vδ2 T cells to the tumor, selectively kill cancer cells and trigger an immune response cascade.  Our Gammabody™ drug candidates have, in preclinical studies, demonstrated superior efficacy and safety profiles compared to other bispecific T cell engagers approaches in preclinical studies and show preferential activity against tumor cells thereby potentially limiting toxicity in healthy tissue. To date, we are the only company developing bispecific gamma delta T cell engaging antibodies for the treatment of cancer.

We are building a pipeline of Gammabody™ drug candidates that have applications in both solid and hematologic malignancies. Our lead program, LAVA-051, targets the tumor-specific antigen CD1d, which can be overexpressed in multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML), among other tumor types. Enrollment is now open in our open-label, multi-center, Phase 1/2a clinical trial of LAVA-051 for the treatment of relapsed and/or refractory CLL, MM and AML. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-051. Click here to learn more about the trial

Our Pipeline